Table 2.
Immunogenicity of different vaccine platform.
| B-B-B (n = 15) | B-C-B (n = 5) | C-C-C (n = 9) | C-C-B (n = 8) | p-Value | |
|---|---|---|---|---|---|
| WT | |||||
| Baseline GMT 1 |
20 (10.8–37.1) 2 | 5.74 (3.91–8.44) | 7.94 (1.09–58) 3 | 5.74 (3.91–8.44) 4 | 0.046 |
| Post-Booster GMT |
306 (154–608) | 106 (17.7–629) | 34.3 (16.3–72.1) | 207 (22.7–1893) | 0.058 |
| GMT fold increase | 15.3 (7.14–32.7) 5 | 18.4 (2.84–119) | 4.32 (1.99–9.37) 5 | 36.1 (4.21–310) 5 | 0.012 |
| BV | |||||
| Baseline GMT |
18.7 (9.46–36.8) 2 | 5 (5–5) | 6.3 (2.33–17) 3 | 5 (5–5) 4 | 0.086 |
| Post-Booster GMT | 175 (95–324) | 106 (25–446) | 18.5 (11.3–30.4) | 87.2 (14.5–523) | 0.148 |
| GMT fold increase | 9.4 (5.77–15.3) 5 | 21.1 (5–89.1) | 2.94 (1.84–4.7) 5 | 17.4 (2.91–105) 5 | 0.026 |
| DV | |||||
| Baseline GMT | 13.2 (8.69–20) 2 | 5 (5–5) | 7.94 (1.09–58) 3 | 5 (5–5) 4 | 0.044 |
| Post-Booster GMT | 184 (81.7–413) | 139 (21.9–900) | 20 (11.7–34.1) | 160 (17.5–1461) | 0.041 |
| GMT fold increase | 13.9 (5.75–33.7) 5 | 27.9 (4.31–180) | 2.52 (1.36–4.66) 5 | 32 (3.5–292) 5 | 0.011 |
| OV | |||||
| Baseline GMT |
5 (5–5) 2 | 5 (5–5) | 5 (5–5) 3 | 5 (5–5) 4 | - |
| Post-Booster GMT |
27.6 (15–51) | 10 (2.25–44.4) | 5.83 (4.61–7.38) | 23.8 (6.45–87.7) | 0.077 |
| GMT fold increase | 5.53 (2.99–10.2) 5 | 2 (0.45–8.88) | 1.17 (0.992–1.42) 5 | 4.76 (1.29–17.5) 5 | 0.077 |
1: data are mean value (95% CI); 2: n = 10, 10 participants recruited before booster dose; 3: n = 3, 3 participants recruited before booster dose; 4: n = 5, 5 participants recruited before booster dose; 5: baseline of participants without baseline is assumed to be the same as mean of those in the same group against that particular virus variant.